Tumour necrosis factor alpha

Overview

Tumour necrosis factor alpha (TNF-α) is a pleiotropic pro-inflammatory cytokine and a major mediator of immune signaling in health and disease. It is produced by multiple cell types, including immune cells, and acts through TNF receptors to regulate inflammation, cell survival, apoptosis, and tissue remodeling. Because of these broad effects, TNF-α is a central node in inflammatory pathways such as nuclear factor-κB signaling and is frequently measured as a biomarker of inflammatory burden.

In biomedical research, TNF-α is also an important therapeutic target. Inhibition or modulation of TNF-α signaling is used to probe inflammatory mechanisms in conditions ranging from periodontitis and myocardial injury to neurodegenerative, respiratory, hepatic, and metabolic disease models. The recent studies summarized below show TNF-α being used both as a readout of inflammatory state and as a direct target for biologic inhibitors, nanomaterials, and small-molecule interventions.

Focus of Latest Publications

Recent publications highlight TNF-α as a key inflammatory mediator across diverse disease contexts.

In a study of a dual-functional hydrogel for concurrent treatment of periodontitis and myocardial infarction, the oral-cardiac inflammatory axis was specifically linked to downregulation of B2 cell/TNF-α signaling. The reported effect was to mitigate systemic inflammation associated with myocardial infarction, suggesting that local periodontal intervention may influence distant cardiovascular inflammation through TNF-α-associated immune pathways.

A structural study using cryo-electron microscopy examined ozoralizumab, a humanized anti-TNF-α NANOBODY® compound. This work focused on the interaction mechanism of the inhibitor with TNF-α and emphasized that the molecule was designed to exert potent inhibitory effects against TNF-α while maintaining a long plasma half-life. This reinforces TNF-α as a validated biologic target for anti-inflammatory drug design.

Several studies used TNF-α as a mechanistic inflammatory stimulus or biomarker. In spinal cord injury research, TNF-α was employed to determine expression profiles of NF-κB in the context of Herkinorin-mediated neuroprotection. In a diabetic liver injury model, TNF-α was described as a key pro-inflammatory cytokine and was implicated in pyroptosis through the HMGB1/TLR4/MyD88/NF-κB pathway, with Gasdermin D, caspase1, and related inflammatory signaling components relevant to the mechanism.

TNF-α also appeared in neuroinflammation-related studies. In experimental Parkinson’s disease, hemorphin LVV-H3 altered cytokine levels, with TNFα decreased in the brain under rotenone exposure. In an Alzheimer therapy study, the dual acetylcholinesterase/butyrylcholinesterase inhibitor IMS48 downregulated TNFα expression alongside APP, BACE1, IL-1α, and IL-1β, consistent with reduced neuroinflammatory signaling. Similarly, knockdown of Glelr in primary microglia enhanced expression of pro-inflammatory cytokines including TNFα and increased phagocytic activity, linking TNF-α to microglial inflammatory programming.

In respiratory and epithelial disease research, TNF-α was used together with IL-17A to create inflammatory conditions that amplified the efficacy of a triple drug combination for rescue of CFTR chloride channel function in nonsense mutation settings. This indicates that TNF-α can potentiate inflammatory stress and alter therapeutic responsiveness in epithelial systems.

TNF-α was also used in cell-based inflammatory models. Lemon balm-derived nanovesicles were tested in human skin fibroblasts exposed to a cytokine cocktail containing IL-22, IL-17A, and TNF-α to induce a pro-inflammatory state, with the study assessing restoration of mitochondrial function and reduction of cytokine production. In HIV research, TNFα served as a latency-reversing stimulus in CD4 T cell lines, where CRISPR/Cas-mediated proviral excision blocked HIV-1 reactivation after stimulation with SAHA and TNFα.

Additional studies positioned TNF-α as a systemic inflammatory marker. A translational aging study reported lower levels of tumour necrosis factor-alpha among inflammation-related markers in old mice after chronic supplementation with a mitochondria-targeted antioxidant. A systematic review and meta-analysis of periodontitis found significantly higher systemic TNF-α levels, supporting its association with chronic oral inflammation. Another meta-analysis on bed rest showed elevated TNF-α in both head-down tilt and horizontal bed rest conditions, consistent with inflammation-related cardiometabolic changes during inactivity.

Across these studies, TNF-α emerges as both a disease-associated cytokine and a practical experimental tool for modeling inflammatory signaling, especially in pathways involving NF-κB, MyD88, HMGB1, IL17A, IL-6, and other proinflammatory cytokines.

Key Publications

• Jun Cryo-EM elucidates the interaction mechanism of ozoralizumab, a humanized anti-TNFα NANOBODY® compound. (Biochemical and biophysical research communications, 2026, PMID 41935434): "OZR is designed as a unique format to exert potent inhibitory effects against TNFα with long plasma half-life."
• Jun Tumour Necrosis Factor-α Promotes Pyroptosis in Diabetic Liver Injury via the HMGB1/TLR4/MyD88/NF-κB Pathway. (Journal of cellular and molecular medicine, 2026, PMID 42219549): "...with tumour necrosis factor-alpha (TNF-α) recognized as a key pro-inflammatory cytokine."
• Jun Herkinorin Exerted Neuroprotective Effects After Spinal Cord Injury by Suppression of NF-κB Pathway Activation. (Neurochemical research, 2026, PMID 42219409): "The TNFα was employed to determine the expression profiles of NF-κB."
• May Hemorphin LVV-H3 attenuates calcineurin activity and regulates cytokine levels in experimental Parkinson's disease. (Neuroscience letters, 2026, PMID 41946390): "IL-2 and TNFα levels were altered differently by rotenone; for example, IL-2 increased and TNFα decreased in the brain."
• May Discovery of a novel IMS48 as a dual inhibitor of acetylcholinesterase and butyrylcholinesterase: In vitro and in vivo study for Alzheimer therapy. (Neuropharmacology, 2026, PMID 41628818): "IMS48 also downregulated the gene expression of AChE (1.56±0.10-fold and 1.71±1.76-fold), APP (1.96±0.17-fold and 3.39±0.139-fold), BACE1 (1.92±0.10-fold and 2.59±0.04-fold), TNFα (2.16±0.21-fold and 3.35±0.17-fold), IL-1α (1.86±0.236-fold and 2.56±0.15-fold), and IL-1β (1.58±1.82-fold and 2.32±0.13-fold), associated with AD pathology and neuroinflammation."
• May Rescue of the CFTR chloride channel with nonsense mutations is markedly improved under inflammatory conditions. (The European respiratory journal, 2026, PMID 41381228): "Importantly, the efficacy of the triple drug combination was greatly amplified under inflammatory conditions, i.e. by exposing the epithelia to interleukin (IL)-4 (15-fold increase) or to IL-17A/tumour necrosis factor-α (nine-fold increase)."
• May lncRNA Glelr modulates microglia inflammatory programs in association with PU.1. (Neurobiology of disease, 2026, PMID 41895620): "Knockdown of Glelr in primary microglia led to enhanced expression of pro-inflammatory cytokines, including TNFα, and increased phagocytic activity."
• Apr Local periodontal injection, systemic heart repair: A dual-functional hydrogel for non-invasive concurrent treatment of periodontitis and myocardial infarction. (Bioactive materials, 2026, PMID 41810018): "Concomitantly, this dual action modulates the oral-cardiac inflammatory axis, specifically downregulating B2 cell/TNF-α signaling to mitigate systemic inflammation associated with MI."
• Apr Bipolar CD4-targeted dual-DARPin-55/57 lipid nanoparticle enables efficient CRISPR/Cas-mediated HIV-1 DNA excision and reactivation blockade in latent CD4 T cell lines. (Materials today. Bio, 2026, PMID 41769381): "Importantly, proviral excision functionally blocked HIV-1 reactivation following stimulation with latency-reversing agents suberoylanilide hydroxamic acid (SAHA) and TNFα."
• Apr Translational studies of chronic supplementation with a mitochondria-targeted antioxidant to improve physical function with ageing. (The Journal of physiology, 2026, PMID 41733122): "The effects of MitoQ in old mice were accompanied by lower levels of skeletal muscle mitochondria-specific superoxide production and markers of mitoROS-related oxidative stress (i.e. phosphorylated SHC adaptor protein 1, isoform p66) and inflammation (i.e. interleukin-6, tumour necrosis factor-alpha, interferon-gamma)."